Media appearances connected to work with PrEP4All and Public Citizen:
TheBody.com, “Breaking Down Three Legal Actions Against Truvada-Maker Gilead.” (Jul. 24, 2024)
STAT, “Biden administration appeals jury finding in battle over patents for HIV prevention pills.” (Jul. 8, 2024)
New York Times, “How a Drugmaker Profited by Slow-Walking a Promising H.I.V. Therapy.” (Jul. 22, 2023)
STAT, “A battle between Gilead and the U.S. government over patents on HIV prevention pills goes to trial.” (May 3, 2023)
Bloomberg Law, “Gilead, US Clash in Billion-Dollar Trial on HIV-Drug Patent.” (May 2, 2023)
Law360, “Gilead, DOJ Allowed To Redact Remaining Docs In Patent Row.” (Apr. 4, 2023)
Bloomberg Law, “US, Gilead Pushed to Explain Sealed Docs in HIV Drug Patent Case.” (March 31, 2023)
Bloomberg Law, “US, Gilead HIV Drug Patent Case Secrecy Spurs Transparency Calls.” (March 15, 2023)
The American Prospect, “Moderna’s COVID Vaccine Price Hike Reveals Government’s Failure.” (January 24, 2023)
STAT News, “Moderna plans to follow in Pfizer’s footsteps, charge up to $130 for Covid-19 vaccine in U.S.” (January 9, 2023)
Wall Street Journal, “Who Invented Covid-19 Vaccines? Drugmakers Battle Over Patents.” (December 29, 2021)
Nature, “What the Moderna-NIH COVID vaccine patent fight means for research.” (November 30, 2021)
New York Times, “Moderna and U.S. at Odds Over Vaccine Patent Rights.” (November 9, 2021)
Jacobin, “Joe Biden Should Share US Vaccine Data With the Rest of the World.” (September 7, 2021)
EPIDEMIC Podcast S1E75: “Vaccinating the World Part I: The Problem with Patents / Chris Morten, Prithi Krishtel & Rohit Malpani.” (May 20, 2021)
Financial Times, “Vaccine patent gives US government ‘leverage’ over manufacturers.” (April 21, 2021)
Bloomberg Law, “Covid-19 Vaccine Deal-Making Is Fleeting Game Changer for Pharma.” (March 29, 2021)
STAT News, “HHS is urged to use its patents for the Moderna Covid-19 vaccine to widen global access.” (March 25, 2021)
New York Times, “Rich Countries Signed Away a Chance to Vaccinate the World.” (March 21, 2021)
San Francisco Chronicle, COVID-19 drug remdesivir has been a big win for Gilead — and it got a boost from taxpayers. (January 27, 2021)
STAT News, “This academic published a manual for using a little-known federal law for lowering drug prices.” (January 26, 2021)
STAT News, “A payoff for U.S. taxpayers? CDC may have claims on remdesivir patents held by Gilead.” (December 7, 2020)
CNN.com, “Covid-19 drug rationed in the US is plentiful in developing countries.” (September 9, 2020)
STAT News, “With remdesivir, Gilead finds itself at strategic crossroads, with its reputation (and far more) at stake.” (May 5, 2020)
TheBody, “PrEP Advocates Call New Gilead Patent Suit Against HHS a ‘Distraction.’” (May 4, 2020)
Bloomberg Law, “Facebook Ads Cause Patients to Stop, Switch HIV Prevention Drug.” (December 16, 2019)
The Advocate, “PrEP4All Claims Gilead Held Back Safer HIV Drug.” (December 5, 2019)
Washington Post, “Gilead delayed safer HIV drug to extend monopoly profits, advocates allege.” (December 5, 2019)
Modern Healthcare, “Gilead pledges to donate Truvada despite HHS patent lawsuit.” (November 7, 2019)
NBC News, “U.S. sues Gilead, claiming it owns HIV PrEP patent.” (November 7, 2019)
Financial Times, “Gilead did not seek US exclusivity on PrEP with Truvada.” (August 18, 2019)
STAT News, “HHS gets a new HIV prevention patent, but will the agency demand royalties from Gilead?” (July 2, 2019)
Bloomberg News, “Gilead’s $21,000 Drug Is Being Blamed for a Plateau in HIV Prevention.” (May 17, 2019)
Bloomberg Law, “HIV Pill Patent Gives Trump Team Leverage in Gilead Price Talks.” (April 12, 2019)
STAT News, “AIDS activists skewer CDC for conflicting stance on collecting HIV drug royalties.” (April 10, 2019)
Washington Post, “An HIV treatment cost taxpayers millions. The government patented it. But a pharma giant is making billions.” (March 26, 2019)
Media appearances connected to work with Charles Seife, Peter Lurie, and UAEM:
STAT News, “For the first time, the FDA may fine a drug maker for failing to post clinical trial results.” (April 28, 2021)
BMJ, “FDA may fine clinical trial sponsors that don’t report data.” (August 24, 2020)
STAT News, “FDA finalizes penalties for clinical trial sponsors that don’t share data, but critics say they fall short.” (August 18, 2020)
STAT News, “Following court ruling, NIH warns drug and device companies to post missing trial data.” (August 4, 2020)
Endpoints News, “Clinical trial sponsors have to disclose decade’s worth of unreleased data, federal judge rules.” (February 26, 2020)
STAT News, “Federal judge rules clinical trial sponsors must publish a decade’s worth of missing data.” (February 25, 2020)
Other media appearances:
Law360, “Justices Hand Abortion Advocates An Incomplete Win.” (Jun. 13, 2024)
Bloomberg Law, “Wave of Amicus Briefs Back Drug Price Plan at Trial Court Stage.” (Apr. 26, 2024)
The Hill, “Drug price negotiations, legal battles set to ramp up: What to expect.” (Feb. 1, 2024)
New York Times, “Six Reasons Drug Prices Are So High in the U.S.” (Jan. 17, 2024)
Behind the News with Doug Henwood — October 19, 2023
Behind the News with Doug Henwood — July 27, 2023
STAT News, “Stéphane Bancel, Bernie Sanders spar over what Moderna owes the federal government.” (March 22, 2023)
Politico, “Sanders readies broadside against Moderna.” (February 17, 2023)
New York Times, “Moderna Sues Pfizer and BioNTech Over Covid Vaccine Technology.” (August 26, 2022)
CNN.com, “Moderna files patent infringement lawsuits against Pfizer and BioNTech over mRNA Covid-19 vaccines.” (August 26, 2022)
Law360, “Big Pharma Expected To Put Up Fight Over Drug Negotiations.” (August 12, 2022)
Bloomberg Government, “Drug Bill Shows Limits of Democrats’ Power.” (August 10, 2022)
CNBC.com, “How HIV research paved the way for the Covid mRNA vaccines.” (December 1, 2021)
Endpoint News, “FDA is much worse than its regulatory peers at proactively disclosing data, researchers find.” (October 26, 2021)
RAPS Regulatory Focus, “Should the US government share the Moderna COVID vaccine recipe?” (September 29, 2021)
Law360, “GSK Redo Doesn't Cure Generics' 'Skinny Label' Uncertainty.” (August 9, 2021)
STAT News, “A federal appeals court throws into question the fate of ‘skinny labels’ — and access to generic drugs.” (August 5, 2021)
STAT News, “Advocates urge Biden to name patent office director that could transform drug pricing.” (July 19, 2021)
Boston Globe, “‘It should send shock waves to the White House’: Backlash over FDA approval of Biogen’s Alzheimer’s drug is spreading.” (June 11, 2021)
Bloomberg Law, “Vaccine IP Enforcement Takes Stage in Global Immunization Fight.” (April 27, 2021)
Jacobin, “Moderna’s Pledge Not to Enforce the Patents on Their COVID-19 Vaccine Is Worthless.” (April 22, 2021)
Bloomberg Law, “Pandemic Lays Bare Fight Over Patent Strength, Innovation.” (August 11, 2020)
Politico, “Trump’s Wild West approach to virus cure-alls is a game-changer for drugmakers.” (April 17, 2020)
STAT News, “Academics and consumer groups protest FDA plan to summarize review documents.” (August 29, 2019)